Pfizer Signs Academic Collaboration Pact With Peking University To Support Translational R&D Center In Shenzhen

SHANGHAI - After unveiling a plan to build a research and development center in Wuhan last week, Pfizer announced it inked an agreement with Peking University Dec. 1 to fund the university's research projects and to build a translational research and drug discovery center in PKU's Graduate School in Shenzhen, a Chinese city that borders the former British enclave of Hong Kong

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Pipeline Growth Slowed In 2024 But Oncology And Neurologicals Held Strong

 

There was a reduction in the rate of expansion of the pharma pipeline last year but 2024 also saw another welcome increase in the number of drug candidates in Phase III following years of stagnation.

New Data Strengthen Case For RemeGen’s Telitacicept In gMG

 

Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

 
• By 

Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.